The biopharma firm cites strong specialty plasma demand and vertical integration as key drivers for its 2026 outlook.
Kamada Ltd. maintained its 2026 revenue guidance of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million, despite a $2.4 million Q1 shipment delay due to Middle East flight restrictions. The delayed order was fulfilled in April, with management emphasizing underlying demand for its specialty plasma portfolio, including KEDRAB and VARIZIG, as a growth catalyst.
The company is advancing vertical integration by expanding three plasma centers to reduce costs and generate revenue from normal source plasma sales. Strategic initiatives include reinforcing CYTOGAM’s market position through post-marketing research and expanding its distribution segment into the MENA region. Growth in the GLASSIA franchise is also targeted in misdiagnosed international markets like Argentina and Russia.
Guidance remains based on organic growth, with no reliance on acquisitions or partnerships.